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Abstract
Recent studies as well as theoretical models of error processing assign fundamental importance to the brain’s dopaminergic
system. Research about how the electrophysiological correlates of error processing—the error-related negativity (ERN) and
the error positivity (Pe)—are influenced by variations of common dopaminergic genes, however, is still relatively scarce. In
the present study, we therefore investigated whether polymorphisms in the DAT1 gene and in the DRD4 gene, respectively,
lead to interindividual differences in these error processing correlates. One hundred sixty participants completed a version
of the Eriksen Flanker Task while a 26-channel EEG was recorded. The task was slightly modified in order to increase error
rates. During data analysis, participants were split into two groups depending on their DAT1 and their DRD4 genotypes,
respectively. ERN and Pe amplitudes after correct responses and after errors as well as difference amplitudes between errors
and correct responses were analyzed. We found a differential effect of DAT1 genotype on the Pe difference amplitude but
not on the ERN difference amplitude, while the reverse was true for DRD4 genotype. These findings are in line with
predictions from theoretical models of dopaminergic transmission in the brain. They furthermore tie results from clinical
investigations of disorders impacting on the dopamine system to genetic variations known to be at-risk genotypes.
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Introduction
Electrophysiological research extensively investigates the gen-
eration of two correlates of error processing: One component, the
error-related negativity (ERN), is a defined negative event-related
potential (ERP) with an amplitude of up to 10 mV that appears in
the response-locked EEG 50 to 100 ms after an erroneous
response [1,2]. The ERN has been theorized to reflect the activity
of an error processing system that detects incorrect motor
commands via a central processing pathway [3] without using
sensory or proprioceptive information [2]. A second component,
the error positivity (Pe), is a slow positive EEG potential that peaks
200 to 400 ms after an error is committed [1,4]. The Pe has been
suggested to represent the conscious detection of an erroneous
response [3,5], an adaptation of response strategy, or the
subjective or emotional evaluation of the error [4].
An influential theoretical model by Holroyd and Coles [6] links
the ERN to processes of reinforcement learning: This model holds
that when an error occurs, the basal ganglia send a dopami-
ne(DA)-mediated negative reinforcement learning signal to the
anterior cingulate cortex (ACC), thereby generating the ERN.
Given the hypothesized role of DA transmission in the
generation of the ERN, several studies investigated error
processing in patients with Huntington’s Disease (HD) and
Parkinson’s Disease (PD), both conditions with altered dopami-
nergic transmission. Beste and colleagues [7] reported reduced
ERN amplitudes in HD patients with decreased amplitudes
correlating with genetic disease load, thereby supporting the
importance of intact striatal functioning for error processing.
Results for PD patients are conflicting [8,9,10], which might in
part be explained by an undesired side effect of dopaminergic PD
medication on error processing [11].
Error processing has also been investigated in patients with
psychiatric disorders, with most research focusing on attention
deficit hyperactivity disorder (ADHD), a disorder which comprises
altered striatal dopamine levels [12]. Many studies report reduced
Pe amplitudes in ADHD patients, a reduction of ERN amplitudes,
however, does not seem consistent across studies [13,14,15,16].
In healthy volunteers, pharmaceutical alteration of dopaminer-
gic transmission in the basal ganglia by a single dose of d-
amphetamine resulted in enlarged ERN amplitudes, which was
attributed to d-amphetamine’s agonistic effect on dopaminergic
transmission [17]. In turn, reducing dopaminergic transmission in
the basal ganglia by using the antipsychotic D2/D3 receptor
antagonist haloperidol led to a significant reduction of ERN
amplitude in healthy participants [11,18,19].
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So far, only few studies of common genotype variations that
influence dopaminergic transmission have been reported and these
are partly contradictory (for a review see [20]). The catechol-O-
methyltransferase (COMT) polymorphism, for example, is known
to influence frontal dopamine levels [21] and was found to affect
Pe but not ERN amplitude in one study [22], whereas another
study [23] did not yield significant findings. The second study,
however, found an effect of a single nucleotide polymorphism
(SNP) that supposedly leads to a reduction of dopamine D4
receptors (DRD4) on ERN but not Pe amplitude [23]. In addition,
functional magnetic resonance imaging studies investigated genetic
polymorphisms influencing dopamine D2 receptor (DRD2)
expression: These receptors are prominently expressed in the
basal ganglia and genetic variations seem to influence the ability to
learn from negative feedback [24,25].
Since previous research seems to support the hypothesized crucial
role of dopaminergic signalling in error processing, we decided to
investigate two new polymorphisms of important genes that
influence dopaminergic transmission in different areas of the brain:
The gene encoding the dopamine transporter (DAT1, SLC6A3)
was found to possess a genetic variation – a 40 nucleotide variable
number of tandem repeats (VNTR) polymorphism in the 39
untranslated region (UTR) – with two common alleles labelled 9-
repeat (9R) and 10-repeat (10R), which supposedly influence gene
expression and thereby DA reuptake from extracellular space
[26,27,28,29,30]. The direction of this influence, however, is not
yet clear, with studies yielding differing results with regard to
which VNTR results in greater DAT expression. The DAT is
primarily expressed in the striatum with only scarce expression in
the prefrontal and medial frontal cortex [31,32]. Two in vivo
SPECT studies of healthy adults showed that the presence of at
least one 9R allele led to increased DAT availability in the
participants’ striatum [33,34], which might indicate increased
striatal dopamine availability in 10/10R carriers.
The dopamine D4 receptor gene (DRD4) also possesses a
polymorphism with a 48 bp variable number of tandem repeats
(VNTR) in exon III, which can vary from 2 to 11 repeats [35,36].
An investigation of human post-mortem brain tissue recently
showed a trend for reduced DRD4 mRNA expression in samples
carrying at least one seven-repeat allele [37]. DRD4 is mainly
expressed in the prefrontal cortex with low levels of expression in
the basal ganglia [36,38].
Based on the model by Holroyd and Coles [6] as well as
previous research outlined above, it is reasonable to expect some
influence of these genes on error processing components: The
DAT1 10/10R genotype was linked to smaller Pe amplitudes in
children with ADHD, but showed no effect on the ERN [39]; a
study of the DRD4 SNP -521C/T found increased ERN amplitudes
for homozygous carriers of the T allele, which supposedly leads to
less transcriptional efficiency [23].
In our experiment, we examined ERN and Pe amplitudes
during a simple reaction time task in an unselected sample of
healthy participants and compared amplitudes according to
participants’ DAT1 and DRD4 genotypes. Based on previous
research, we expected the DAT1 10R genotype to be linked to




Ethical approval was obtained through the Ethical Review
Board of the medical faculty of the University of Wu¨rzburg (vote
131/04); all procedures involved were in accordance with the 2008
Declaration of Helsinki. Participants gave written informed
consent after full explanation of the procedures.
Participants
One hundred sixty subjects (70 male, 90 female) participated in
this study. Mean (M) age was 27.02 years, ranging from 20 to 50
years of age (standard deviation SD =7.28). All participants were
right-handed, without any medication, and never treated for
neurologic or psychiatric problems. Results from a subsample
(n = 56) have been published elsewhere [16,40].
Participants were stratified into a homozygous 10/10R group
(n= 98) and a group carrying at least one 9R allele (9/9R or 9/
10R; n = 62) according to their DAT1 VNTR genotype. Addi-
tionally, participants were stratified based to their DRD4 VNTR
genotype into a 7R group (at least one 7R allele; n = 46) and a no
7R group (n= 114). DAT1 and DRD4 subgroups did not differ
significantly with respect to gender, age, symptoms of depression,
reaction time for correct answers, number of errors, and number
of trials without artefacts per condition (as assessed with t-tests, all
p..05). The severity of ADHD symptoms as assessed with the
ADHD Self-Report Scale (ASRS) differed between DAT1
subgroups, with increased values for the 9R group compared to
the 10/10R group (t(158) = 2.66, p= .009; see table 1 for details).
Psychological Assessment
Participants completed an 18 item screening questionnaire [41]
based on the diagnostic criteria of ADHD as stated in the DSM-
IV-TR [42]. It measures the frequency of ADHD symptoms
ranging from 0 (‘never’) to 4 (‘very often’). Additionally, the Beck
Depression Inventory (BDI, [43]) was used to assess depressive
symptoms.
Stimuli and Procedure
We used a modified version of the Eriksen Flanker Task [44] as
published before [16,40]. Since the focus of this study was on
neural correlates of error processing, the task was adapted to
obtain high error rates. One of four possible combinations of
arrows (,,.,,, ..,.., .,.,., ,.,.,) was shown
in the middle of a 159 monitor for 125ms. Stimuli were presented
in random order, with the probability of occurrence being .25 for
each combination. Subjects completed 160 trials twice, with a
short break in between, where they had to indicate the direction of
the middle arrow as quickly and as accurately as possible with their
left (,) and right (.) index finger, respectively. Feedback was
given 750 ms after the response by showing a plus sign (correct
response), a minus sign (incorrect/no response), or an exclamation
mark (correct response outside the reaction time limit) in the
centre of the screen for 500 ms. The interstimulus interval varied
between 500 ms and 1000 ms. The reaction time limit was
determined individually in a practice session – which consisted of
40 trials with a 500 ms time limit – and the mean reaction time
over all correct trials was adapted as reaction time limit for the
subsequent experimental task. This time limit served to increase
error rates. However, all responses (including ‘‘late’’ responses)
were subsequently analyzed.
EEG Acquisition and Analyses
Event-related potentials were recorded from 26 Ag/AgCl scalp
electrodes. Besides the recording sites specified in the 10–20
system, electrodes were placed on Oz, Fpz, under the right eye and
on its outer canthus, and on the left and right mastoids. Impedance
was kept below 5 kV for all electrodes. The ground electrode was
placed between Fz and Fpz. Sampling rate was 1000 Hz, with the
Impact of DAT1, DRD4 Genotypes on Error Processing
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amplifier band pass filter set to 0.1–70 Hz and the notch filter set
to 50 Hz. All data were recorded in relation to a midline reference
placed between Cz and Fz and re-referenced offline to an average
reference.
Eye movement artefacts were corrected [45] and response-
locked EEG epochs from 2200 ms to 500 ms were defined
separately for correct and incorrect responses. Artefact-free epochs
(no voltage in any channel exceeding 6100 mV or showing drops
or rises of more than 100 mV/ms) were averaged: For incorrect
responses, an average of 52.06 (SD =33.01) epochs and for correct
responses, an average of 260.80 (SD =52.29) epochs were
averaged.
Baseline correction based on the mean amplitude from
2200 ms to 0 ms was implemented, and the time windows to
detect ERN and Pe peaks were subsequently determined based on
the grand average time curve over all subjects. The ERN was then
automatically identified as the negative peak value between
235 ms and 108 ms over the electrode position Cz; the Pe was
analogically detected as the positive peak value between 110 ms
and 450 ms.
ERP amplitudes were analysed separately for the ERN and the
Pe by using an analysis of variance (ANOVA) with the factors
condition (correct, incorrect) and genotype (DAT1 (9R group vs.
10/10R group) and DRD4 (no 7R vs. 7R)). Two-sided t-tests were
used for post-hoc analyses. For all analyses, p-values below .05
were considered significant.
Genotyping
Genomic DNA was extracted from whole blood samples by salt
precipitation according to standard protocols. Genotyping of the
DAT1 VNTR was performed by polymerase chain reaction (PCR)
and subsequent gel electrophoresis as published previously [46].
Genotyping for the DRD4 VNTR was accomplished using
standard PCR procedures modified from a previously published
protocol [47]. Further details on protocols are available upon
request.
Results
There was a main effect for response time following an
erroneous as compared to a correct response (F[1,156] = 90.25,
p,.001; post-correct responses: M=452.21 ms, SD=56.41; post-
error responses: M=476.90 ms, SD=68.01), showing significant
post-error slowing across all genotype groups. There was no main
effect of DAT1 genotype (F[1,156] = .82, p= .366) or DRD4
genotype (F[1,156] = .05, p= .831) and no interaction effects.
Participants gave an average of 267.87 correct responses
(SD=51.13). There was no main effect of DAT1 genotype
(F[1,156] = .16, p= .690) or DRD4 genotype (F[1,156] = 1.01,
p= .318) as well as no interaction effects.
For the ERN, we found a main effect of condition
(F[1,156] = 144.96, p,.001) with incorrect responses leading to
more negative values than correct ones and an interaction effect of
condition and DRD4 genotype (F[1,156] = 5.37, p= .022), which is
discussed below. We did not find an interaction effect of condition
and DAT1 genotype (F[1,156] = .40, p= .526), or a three-way
interaction effect of condition, DAT1 genotype, and DRD4
genotype (F[1,156] = .66, p= .419). In addition, no main effects of
DAT1 genotype (F[1,156] = .73, p= .394) or DRD4 genotype
(F[1,156] = .17, p= .685) were found.
The significant interaction effect of condition and DRD4
genotype can be described by significantly smaller difference
amplitudes between the correct and incorrect response conditions
in 7R carriers compared to no 7R carriers (t(158) =22.18, p= .031;
see table 2 for M, SD, and post-hoc t-tests; figure 1).
For the Pe, we also found a main effect of condition
(F[1,156] = 197.70, p,.001) with incorrect responses leading to
more positive values than correct ones and an interaction effect of
condition and DAT1 genotype (F[1,156] = 4.78, p= .030), which is
discussed below. We did not find an interaction effect of condition
and DRD4 genotype (F[1,156] = .01, p= .972) or a three-way
interaction effect of condition, DAT1 genotype, and DRD4
genotype (F[1,156] = .99, p= .321). Furthermore, no main effects
of DAT1 genotype (F[1,156] = .34, p= .562) or DRD4 genotype
(F[1,156] ,.001, p= .987) were found.
The significant interaction effect can be described by marginally
smaller difference amplitudes between the correct and incorrect
response conditions in 9R carriers (t(158) =21.97, p= .051; see
table 2). A tendency for increased amplitudes of the Pe to correct
reactions in 9R carriers (t(158) = 1.77, p= .079; see table 2 and
figure 1) suggests that the interaction effect was mainly but not
solely caused by differences in the processing of correct responses.
Discussion
We found the ERN amplitude to be related to participants’
DRD4 genotype but not to their DAT1 genotype, whereas the
reverse was true for the Pe amplitude. It therefore seems that the
Table 1. Mean and standard deviation of demographic data, psychiatric symptoms, reaction time in milliseconds, and artefact-free
trials.
DAT1 DRD4
9R 10/10R no 7R 7R
n (female) 62 (31) 98 (59) 114 (66) 46 (24)
Age 27.34 (7.56) 26.82 (7.14) 27.11 (7.64) 26.80 (6.40)
Symptoms of depression 3.29 (3.41) 4.36 (3.93) 3.93 (3.92) 3.98 (3.36)
ADHD symptoms 24.93 (8.22)* 21.62 (7.17)* 22.75 (7.54) 23.23 (8.30)
Reaction time 448.57 (62.81) 460.50 (52.38) 455.21 (60.63) 457.54 (46.35)
Number of errors 59.48 (38.12) 52.53 (30.78) 55.15 (34.66) 55.41 (32.18)
Artefact-free trials correct 261.21 (66.25) 260.54 (41.50) 260.89 (53.78) 260.57 (48.98)
Artefact-free trials incorrect 55.42 (36.26) 49.94 (30.79) 51.41 (33.80) 53.67 (31.26)
Standard deviations are shown in parentheses; significant differences are marked with *.
doi:10.1371/journal.pone.0028396.t001
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DRD4 genotype influences the ERN – defined as the difference
wave between incorrect and correct responses – but not the Pe. In
turn, DAT1 genotype seems to influence the Pe – also defined as
the difference wave – but not the ERN.
According to the model by Holroyd and Coles [6] mentioned
above, the amplitude of the ERN should be influenced by phasic
changes in dopaminergic transmission in the basal ganglia.
Although our results seem to contradict this prediction – DRD4
is mostly expressed in the cortex with very little expression in
striatal areas [36,38] – Rubinstein and colleagues [48] discovered
that mice lacking dopamine D4 receptors showed elevated
dopamine synthesis and conversion in the striatum. This was
Figure 1. Grand average difference curves and peak topographies for DAT1 (A) and DRD4 (B) subgroups. Peak topographies for the ERN
are at 40 ms, for the Pe at 218 ms.
doi:10.1371/journal.pone.0028396.g001
Table 2. Mean and standard deviation of the amplitudes for the different conditions and genotypes.
DAT1 DRD4
9R 10/10R t1-value (p) no 7R 7R t1-value (p)
ERN
– correct 1.01 (2.22) .70 (2.56) .77 (.442) .95 (2.34) .49 (2.66) 1.08 (.281)
– incorrect 22.78 (3.06) 23.18 (3.43) .76 (.451) 23.24 (3.29) 22.48 (3.27) 21.32 (.187)
– difference 23.78 (3.30) 23.88 (3.23) .189 (.850) 24.19 (3.01) 22.98 (3.65) 22.18 (.031)*
Pe
– correct 5.16 (3.55) 4.12 (3.68) 1.77 (.079)+ 4.53 (3.41) 4.52 (4.25) .02 (.984)
– incorrect 8.96 (3.24) 8.99 (3.64) 2.05 (.957) 8.92 (3.45) 9.12 (3.59) 2.32 (.753)
– difference 3.80 (3.37) 4.87 (3.36) 21.97 (.051) + 4.40 (3.24) 4.60 (3.78) 2.34 (.731)
Standard deviations are shown in parentheses; significant differences are marked with *, trends are marked with +; 1 df = 158, two-sided tests.
doi:10.1371/journal.pone.0028396.t002
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possibly caused by glutamatergic transmission from cortical
regions and still has to be investigated in humans. It would,
however, offer a plausible explanation for our findings.
Based on Bilder and colleagues’ [49] model of tonic and phasic
dopamine transmission, lower cortical expression of the DRD4 in
7R carriers could result in compensatorily elevated tonic dopamine
levels in the striatum. This elevation in tonic striatal dopamine
would make 7R carriers less sensitive to changes in phasic
dopamine transmission, which could explain their reduced ERN
amplitude. A similar argument was proposed by Kra¨mer and
colleagues [23], who found an increased ERN amplitude to be
related to the DRD4 SNP -521C/T. However, while the impact of
this SNP on gene expression is still under debate [50,51] we can be
fairly confident about the transcriptional consequences of the
VNTR we investigated.
The results can also be supported from a clinical perspective:
ERN amplitude has been connected to self-reported impulsivity
with highly impulsive individuals showing lower amplitudes [52].
Impulsivity, on the other hand, was recently linked to the presence
of at least one 7R allele [53]. It would therefore seem logical to find
lower ERN amplitudes in 7R carriers.
Regarding DAT1, our findings seem to be at odds with a study
in children that found smaller Pe amplitudes in 10/10R carriers
[39]. The 10R allele has been associated with childhood ADHD
[54] which in turn has been associated with decreased Pe
amplitudes [13,14,55]. Recent studies, however, point to a
differential impact of this VNTR in childhood as compared to
adulthood [56,57]: In adults, carrying the 9R allele was associated
with persistent ADHD and worse cognitive functioning, respec-
tively.
In addition, a recent SPECT study reported a 9R haplotype
which showed significantly higher DAT expression than all other
investigated haplotypes [34]. This led the authors to suggest that
reported higher striatal dopamine transporter availability in 9R
carriers could mainly be caused by this specific subgroup. It might
therefore be interesting and more informative to investigate Pe
amplitudes in participants carrying this haplotype and compare
them to all other haplotypes.
The findings of van de Giessen and colleagues [34] underscore
the importance of basic research into the effects of VNTRs and
SNPs as well as haplotypes on gene expression. While the
interpretation of our results relies on the findings of these studies,
reports on the effects of a certain genetic variation on gene
expression are still often contradictory.
Limitations of the present study are linked to the sample size:
Although representing a rather large sample in neurophysiological
genetic research, power considerations arise from a general genetic
research perspective. The sample size seemed sufficient assuming
an intermediate effect size, and effect sizes of Cohen’s d= .38 were
found for the ERN amplitude depending on participants’ DRD4
genotype and of d= .32 for the Pe amplitude depending on
participants’ DAT1 genotype. A post-hoc power calculation (two-
tailed) revealed a probability of detecting a true significant
difference of 58 and 50 percent, respectively. For the non-
significant findings, effect sizes were d#.06, indicating that these
results represent non-meaningful and practically irrelevant effects.
Furthermore, it would have been interesting to investigate gene-
gene interactions. However, this procedure would have resulted in
four – partly very small – subgroups, which would likely obscure
the effects. Even though this could therefore not be implemented,
both our DAT1 and DRD4 groups are very comparable with
regard to demographic data, psychiatric symptoms, reaction time,
and artefact-free trials. The only group difference was found for
the DAT1 9R and 10/10R groups with regard to their symptoms of
ADHD. This is in line with the current literature [56,57], and
further helps to tie clinical findings of reduced Pe amplitudes in
ADHD to an identified genetic risk factor.
Although we did not find any results on the behavioral level, our
study is able to link previously observed error processing deficits in
impulsive and ADHD participants to genetic variants that are
known to contribute to these disorders.
Author Contributions
Conceived and designed the experiments: MJH PS AR. Performed the
experiments: MJH. Analyzed the data: MJH SCB TD JD. Contributed
reagents/materials/analysis tools: MJH AR JD PS. Wrote the paper: SCB
TD MJH.
References
1. Falkenstein M, Hohnsbein J, Hoormann J, Blanke L (1991) Effects of crossmodal
divided attention on late ERP components: II. Error processing in choice
reaction tasks. Electroencephalogr Clin Neurophysiol 78: 447–455.
2. Gehring WJ, Goss B, Coles MGH, Meyer DE, Donchin E (1993) A neural
system for error detection and compensation. Psychol Sci 4: 385–390.
3. Nieuwenhuis S, Ridderinkhof K, Blom J, Band G, Kok A (2001) Error-related
brain potentials are differentially related to awareness of response errors:
evidence from an antisaccade task. Psychophysiology 38: 752–760.
4. Falkenstein M, Hoormann J, Christ S, Hohnsbein J (2000) ERP components on
reaction errors and their functional significance: a tutorial. Biol Psychol 51:
87–107.
5. Endrass T, Reuter B, Kathmann N (2007) ERP correlates of conscious error
recognition: aware and unaware errors in an antisaccade task. Eur J Neurosci
26: 1714–1720.
6. Holroyd CB, Coles MGH (2002) The neural basis of human error processing:
reinforcement learning, dopamine, and the error-related negativity. Psychol Rev
109: 679–709.
7. Beste C, Saft C, Andrich J, Gold R, Falkenstein M (2006) Error processing in
Huntington’s disease. PLoS One 1.
8. Holroyd CB, Praamstra P, Plat E, Coles MGH (2002) Spared error-related
potentials in mild to moderate Parkinson’s disease. Neuropsychologia 40:
2116–2124.
9. Falkenstein M, Hielscher H, Dziobek I, Schwarzenau P, Hoormann J, et al.
(2001) Action monitoring, error detection, and the basal ganglia: an ERP study.
Neuroreport 12: 157.
10. Willemssen R, Mu¨ller T, Schwarz M, Hohnsbein J, Falkenstein M (2008) Error
processing in patients with Parkinson’s disease: the influence of medication state.
J Neural Transm 115: 461–468.
11. Jocham G, Ullsperger M (2009) Neuropharmacology of performance monitor-
ing. Neurosci Biobehav Rev 33: 48–60.
12. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K (2000) Increased striatal
dopamine transporter in adult patients with attention deficit hyperactivity
disorder: effects of methylphenidate as measured by single photon emission
computed tomography. Neurosci Lett 285: 107–110.
13. Jonkman L, van Melis J, Kemner C, Markus C (2007) Methylphenidate
improves deficient error evaluation in children with ADHD: an event-related
brain potential study. Biol Psychol 76: 217–229.
14. Wiersema J, Van der Meere J, Roeyers H (2005) ERP correlates of impaired
error monitoring in children with ADHD. J Neural Transm 112: 1417–
1430.
15. Liotti M, Pliszka S, Perez R, Kothmann D, Woldorff M (2005) Abnormal brain
activity related to performance monitoring and error detection in children with
ADHD. Cortex 41: 377–388.
16. Herrmann MJ, Mader K, Schreppel T, Jacob CP, Heine M, et al. (2010) Neural
correlates of performance monitoring in adult patients with attention
deficit hyperactivity disorder (ADHD). World J Biol Psychiatry 11: 457–
464.
17. de Bruijn ERA, Hulstijn W, Verkes RJ, Ruigt GSF, Sabbe BGC (2004) Drug-
induced stimulation and suppression of action monitoring in healthy volunteers.
Psychopharmacology 177: 151–160.
18. de Bruijn ERA, Sabbe BGC, Hulstijn W, Ruigt GSF, Verkes RJ (2006) Effects of
antipsychotic and antidepressant drugs on action monitoring in healthy
volunteers. Brain Research 1105: 122–129.
19. Zirnheld PJ, Carroll CA, Kieffaber PD, O’Donnell BF, Shekhar A, et al. (2004)
Haloperidol impairs learning and error-related negativity in humans. J Cogn
Neurosci 16: 1098–1112.
Impact of DAT1, DRD4 Genotypes on Error Processing
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28396
20. Ullsperger M (2010) Genetic association studies of performance monitoring and
learning from feedback: the role of dopamine and serotonin. Neurosci Biobehav
Rev 34: 649–659.
21. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, et al. (2003)
Executive subprocesses in working memory: relationship to catechol-O-
methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry
60: 889.
22. Frank MJ, D’Lauro C, Curran T (2007) Cross-task individual differences in
error processing: neural, electrophysiological, and genetic components. Cogn
Affect Behav Neurosci 7: 297–308.
23. Kra¨mer UM, Cunillera T, Camara E, Marco-Pallares J, Cucurell D, et al. (2007)
The impact of catechol-O-methyltransferase and dopamine D4 receptor
genotypes on neurophysiological markers of performance monitoring.
J Neurosci 27: 14190–14198.
24. Klein TA, Neumann J, Reuter M, Hennig J, Von Cramon DY, et al. (2007)
Genetically determined differences in learning from errors. Science 318: 1642.
25. Jocham G, Klein TA, Neumann J, Von Cramon DY, Reuter M, et al. (2009)
Dopamine DRD2 polymorphism alters reversal learning and associated neural
activity. J Neurosci 29: 3695.
26. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, et al. (2001) The VNTR
polymorphism of the human dopamine transporter (DAT1) gene affects gene
expression. Pharmacogenomics J 1: 152–156.
27. Michelhaugh SK, Fiskerstrand C, Lovejoy E, Bannon MJ, Quinn JP (2001) The
dopamine transporter gene (SLC6A3) variable number of tandem repeats
domain enhances transcription in dopamine neurons. J Neurochem 79:
1033–1038.
28. Mill J, Asherson P, Browes C, D’Souza U, Craig I (2002) Expression of the
dopamine transporter gene is regulated by the 3 ’ UTR VNTR: evidence from
brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 114:
975–979.
29. Miller GM, Madras BK (2002) Polymorphisms in the 3 ’-untranslated region of
human and monkey dopamine transporter genes affect reporter gene expression.
Mol Psychiatry 7: 44–55.
30. VanNess SH, Owens MJ, Kilts CD (2005) The variable number of tandem
repeats element in DAT1 regulates in vitro dopamine transporter density. BMC
Genet 6.
31. Lewis DA, Melchitzky DS, Sesack SR, Whitehead RE, Auh S, et al. (2001)
Dopamine transporter immunoreactivity in monkey cerebral cortex: regional,
laminar, and ultrastructural localization. J Comp Neurol 432: 119–136.
32. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI (1998) Dopamine
axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit
sparse immunoreactivity for the dopamine transporter. J Neurosci 18:
2697–2708.
33. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, et al. (2005)
Increased dopamine transporter availability associated with the 9-repeat allele of
the SLC6A3 gene. J Nucl Med 46: 745–751.
34. van de Giessen EM, de Win MML, Tanck MWT, van den Brink W, Baas F,
et al. (2009) Striatal dopamine transporter availability associated with
polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med 50:
45–52.
35. Schoots O, Van Tol HHM (2003) The human dopamine D4 receptor repeat
sequences modulate expression. Pharmacogenomics J 3: 343–348.
36. Oak JN, Oldenhof J, Van Tol HHM (2000) The dopamine D-4 receptor: one
decade of research. Eur J Pharmacol 405: 303–327.
37. Simpson J, Vetuz G, Wilson M, Brookes KJ, Kent L (2010) The DRD4 receptor
exon 3 VNTR and 5 ’ SNP variants and mRNA expression in human post-
mortem brain tissue. Am J Med Genet B 153B: 1228–1233.
38. Meador-Woodruff JH, Damask SP, Wang JC, Haroutunian V, Davis KL, et al.
(1996) Dopamine receptor mRNA expression in human striatum and neocortex.
Neuropsychopharmacology 15: 17–29.
39. Althaus M, Groen Y, Wijers AA, Minderaa RB, Kema IP, et al. (2010) Variants
of the SLC6A3 (DAT1) polymorphism affect performance monitoring-related
cortical evoked potentials that are associated with ADHD. Biol Psychol 85:
19–32.
40. Herrmann MJ, Saathoff C, Schreppel TJ, Ehlis AC, Scheuerpflug P, et al. (2009)
The effect of ADHD symptoms on performance monitoring in a non-clinical
population. Psychiatry Res 169: 144–148.
41. Kessler RC, Adler L, Ames M, Delmer O, Faraone S, et al. (2005) The World
Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening
scale for use in the general population. Psychol Med 35: 245–256.
42. American Psychiatric Association (APA) (2000) Diagnostic and statistical manual
of mental disorders, text revision: DSM-IV-TR. Washington DC: American
Psychiatric Association.
43. Hautzinger M, Bailer M, Worall H, Keller F (1994) Beck-Depressions-Inventar
(BDI). Bern: Huber.
44. Eriksen BA, Eriksen CW (1974) Effects of noise letters upon identification of a
target letter in a nonsearch task. Percept Psychophys 16: 143–149.
45. Gratton G, Coles MGH, Donchin E (1983) A new method for off-line removal
of ocular artefacts. Electroencephalogr Clin Neurophysiol 55: 468–484.
46. Hu¨nnerkopf R, Strobel A, Gutknecht L, Brocke B, Lesch KP (2007) Interaction
between BDNF Val66Met and dopamine transporter gene variation influences
anxiety-related traits. Neuropsychopharmacology 32: 2552–2560.
47. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, et al. (1996) Dopamine
D4 receptor (D4DR) exon III polymorphism associated with the human
personality trait of Novelty Seeking. Nat Genet 12: 78–80.
48. Rubinstein M, Phillips TJ, Bunzow JR, Falzone TL, Dziewczapolski G, et al.
(1997) Mice lacking dopamine D4 receptors are supersensitive to ethanol,
cocaine, and methamphetamine. Cell 90: 991–1001.
49. Bilder RM, Volavka J, Lachman HM, Grace AA (2004) The catechol-O-
methyltransferase polymorphism: relations to the tonic-phasic dopamine
hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29:
1943–1961.
50. Kereszturi E, Kiraly O, Barta C, Molnar N, Sasvari-Szekely M, et al. (2006) No
direct effect of the-521 C/T polymorphism in the human dopamine D4 receptor
gene promoter on transcriptional activity. BMC Mol Biol 7.
51. Okuyama Y, Ishiguro H, Nankai M, Shibuya H, Watanabe A, et al. (2000)
Identification of a polymorphism in the promoter region of DRD4 associated
with the human novelty seeking personality trait. Mol Psychiatry 5: 64–69.
52. Potts G, George M, Martin L, Barratt E (2006) Reduced punishment sensitivity
in neural systems of behavior monitoring in impulsive individuals. Neurosci Lett
397: 130–134.
53. Garcia JR, MacKillop J, Aller EL, Merriwether AM, Wilson DS, et al. (2010)
Associations between dopamine D4 receptor gene variation with both infidelity
and sexual promiscuity. PLoS One 5.
54. Thapar A, O’Donovan M, Owen MJ (2005) The genetics of attention deficit
hyperactivity disorder. Hum Mol Genet 14: R275–R282.
55. Overtoom CCE, Kenemans JL, Verbaten MN, Kemmer C, van der Molen MW,
et al. (2002) Inhibition in children with attention-deficit/hyperactivity disorder: a
psychophysiological study of the stop task. Biol Psychiatry 51: 668–676.
56. Franke B, Vasquez AA, Johansson S, Hoogman M, Romanos J, et al. (2010)
Multicenter analysis of the SLC6A3/DAT1 VNTR haplotype in persistent
ADHD suggests differential involvement of the gene in childhood and persistent
ADHD. Neuropsychopharmacology 35: 656–664.
57. Dresler T, Ehlis A-C, Heinzel S, Renner TJ, Reif A, et al. (2010) Dopamine
transporter (SLC6A3) genotype impacts neurophysiological correlates of
cognitive response control in an adult sample of patients with ADHD.
Neuropsychopharmacology 35: 2193–2202.
Impact of DAT1, DRD4 Genotypes on Error Processing
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28396
